Jesper Lau, Ph.D.Vice President, Chemical Biology at Novo Nordisk A/S
Agenda Sessions
Keynote Introduction by Session Chair and KEYNOTE PRESENTATION with Live Q&A - Discovery and Development of Semaglutide – The First Orally Available GLP-1 Peptide for Treatment of Type 2 Diabetes
10:15amView SessionSESSION NAME: Cutting-Edge Technologies for Peptide Discovery - SESSION CHAIR & SPEAKERS BELOW
On DemandView Session